Memorial Health University Medical Center is participating in a clinical trial to evaluate the safety and effectiveness of pulsed-field ablation to treat atrial fibrillation (Afib). The AdmIRE clinical study will enroll more than 400 patients. It is sponsored by Biosense Webster, Inc. Memorial Health enrolled the first patient in the US for this important study.

Afib is a common type of cardiac arrhythmia and is often treated using ablation. During an ablation procedure, heat or cold is used to create scars to correct irregular heartbeats. The new technology in this clinical trial is being evaluated for its safety and effectiveness with cardiac arrhythmias. Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia affecting an estimated 33 million people globally1. By 2030 the number of people with AF is projected to increase by up to 70 percent2.

David Newton, MD, electrophysiologist with Memorial Health, is a principal investigator in the AdmIRE study. “With Atrial Fibrillation continuing to grow in prevalence around the world, electrophysiologists are looking for innovative approaches that will drive procedure efficiency and help us deliver better patient outcomes. I am pleased to be part of the AdmIRE clinical study to evaluate this investigational PFA solution for electrophysiology mapping and ablation procedures,” said Newton. Another Memorial Health electrophysiologist, Todd Senn, MD, is also participating in the clinical study.

Visit clinicaltrials.gov to learn more about the AdmIRE study.

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-47.

2. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 6: 213-220.

Leave a comment